Business context and reporting period
Johnson & Johnson’s Form 10-K covers the fiscal year ended January 2, 2011; it is an annual report, not a standalone fourth-quarter filing. The company operated through more than 250 subsidiaries in approximately 60 countries, with about 114,000 employees. Its businesses span Consumer, Pharmaceuticals, and Medical Devices and Diagnostics.
Financial and operating metrics
- Revenue, net income, margins, cash flow, debt, and liquidity figures are not provided in the supplied filing text; the 10-K incorporates the detailed financial statements and management discussion from the 2010 Annual Report.
- Worldwide research and development expense was $6.8 billion in 2010, compared with $7.0 billion in 2009 and $7.6 billion in 2008.
- REMICADE, the company’s largest product, represented approximately 7% of 2010 total revenue. LEVAQUIN represented approximately 2% of 2010 sales.
- The company completed its previously announced $10 billion share-repurchase program by January 2, 2011, repurchasing about 158.3 million shares since inception. Fourth-quarter purchases totaled approximately 20.3 million shares.
Material changes versus prior periods
- TOPAMAX faced generic competition after losing U.S. patent protection and market exclusivity in March 2009. Its sales declined 53.3% in 2010, following a 57.9% decline in 2009.
- R&D expense declined to $6.8 billion from $7.0 billion in 2009.
- Production at McNeil Consumer Healthcare’s Fort Washington, Pennsylvania facility was suspended in the second quarter of 2010. The company planned alternate product supplies for the latter half of 2011.
Outlook, risks, contingencies, and unusual items
- The filing text does not provide a clear quantified earnings or revenue outlook. It states that worldwide sales are not significantly seasonal, although advertising and R&D spending tends to be heavier in the fourth quarter.
- McNeil submitted a remediation action plan to the FDA in July 2010 covering training, resources, and quality and manufacturing-system investments. The company reported that it was on schedule with its commitments and continued discussions with the FDA.
- Patent expiration and generic competition are material risks. LEVAQUIN’s U.S. market exclusivity, including a pediatric extension, was scheduled to end June 20, 2011.
- The company cites increasingly stringent regulation, pricing and reimbursement pressures, product safety and recall risks, competition, and political and economic uncertainty in some international markets.
- The company is involved in environmental remediation proceedings under Superfund and comparable laws; management stated these were not expected to materially adversely affect results, cash flows, or financial position. Other legal proceedings are incorporated by reference, and their details are not provided in the supplied text.
- Management reported effective disclosure controls and effective internal control over financial reporting as of January 2, 2011; the independent auditor audited internal-control effectiveness.
Important facts for investors to verify
- Review the incorporated 2010 Annual Report for complete revenue, earnings, segment results, cash flows, debt, liquidity, and margin data.
- Assess the commercial and financial impact of McNeil’s facility suspension, FDA remediation, and planned alternate supplies.
- Evaluate exposure to patent expirations and generic competition, including the post-June 2011 LEVAQUIN transition.
- Review the incorporated legal-proceedings disclosures for case-specific exposures, outcomes, and reserves.
- Confirm capital allocation and share-repurchase activity against the full financial statements and cash-flow disclosures.